Back to Results
First PageMeta Content
CTLA-4 / Protein kinase inhibitor / Bristol-Myers Squibb / Ipilimumab / Melanoma


Toxicity from Checkpoint Inhibitors James Larkin FRCP PhD Disclosures
Add to Reading List

Document Date: 2015-05-04 13:05:47

Open Document

File Size: 541,16 KB

Share Result on Facebook

Company

Checkpoint / Pfizer / Eisai / Genentech / Novartis / /

Event

FDA Phase / /

Facility

Checkpoint Inhibitors James Larkin FRCP PhD Disclosures / /

MedicalCondition

Melanoma / trials Melanoma / Anti-CTLA4 ipilimumab melanoma / tumour / NSCLC / /

Organization

FDA / /

Product

RCC / PD1s / /

SocialTag